Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$3.5 - $5.68 $82,631 - $134,099
-23,609 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$3.44 - $6.37 $81,214 - $150,389
23,609 New
23,609 $122,000
Q2 2021

Aug 12, 2021

SELL
$3.86 - $5.78 $180,424 - $270,168
-46,742 Closed
0 $0
Q1 2021

May 13, 2021

BUY
$4.9 - $6.83 $229,035 - $319,247
46,742 New
46,742 $248,000
Q3 2018

Nov 09, 2018

SELL
$8.27 - $13.56 $124,223 - $203,684
-15,021 Closed
0 $0
Q2 2018

Aug 07, 2018

BUY
$10.42 - $13.74 $156,518 - $206,388
15,021 New
15,021 $178,000
Q1 2018

May 03, 2018

SELL
$7.1 - $11.56 $192,502 - $313,426
-27,113 Closed
0 $0
Q4 2017

Feb 09, 2018

BUY
$6.68 - $8.74 $181,114 - $236,967
27,113
27,113 $181,000

Others Institutions Holding ADAP

About Adaptimmune Therapeutics PLC


  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $47.4M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Trexquant Investment LP Portfolio

Follow Trexquant Investment LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

News

Stay updated on Trexquant Investment LP with notifications on news.